Acquisition Growth ARG has been acquired by Evestia Clinical, creating a leading mid-tier CRO with expanded global reach and full-service trial capabilities. This presents cross-sell opportunities to Evestia’s and ARG’s combined client bases, as well as potential access to a broader global network for oncology, immunology, and neurology trials.

Therapeutic Breadth ARG specializes in oncology, immunology, and neurology with experience in planning to commercialization and more than 50 market authorizations. Leverage this depth to position expanded clinical development services, data analytics, and device/drug strategy offerings to current and prospective sponsors seeking end-to-end support.

Global Expansion Historical office expansion to Munich and recent global integration through Evestia Clinical indicate growing international capabilities. This supports targeting sponsors with global trial needs and the ability to offer local expertise across Europe and other regions.

Strategic Partnerships Past collaborations with BPL and other manufacturers show ARG’s strength in forming alliance-based programs. Use this track record to pursue co-development or supplier-partner opportunities, including device and plasma-derivative therapy programs aligned with CRO services.

Growth Signals Revenue in the multi-million-dollar range, leadership hiring in scientific affairs and operations, and a clear trajectory of expansion signal readiness for larger, multi-study programs. Approach for enterprise-level trials, expanded data analytics, and scalable project management offerings.